These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 33206262

  • 1. PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.
    Robles G, Sauermilch D, Gandhi M, Starks TJ.
    AIDS Behav; 2021 Apr; 25(4):1299-1305. PubMed ID: 33206262
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H, Louie A, Phung N, Zhang K, Tallerico RM, Kuncze K, Spinelli MA, Koss CA, Benet LZ, Gandhi M.
    Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
    [Abstract] [Full Text] [Related]

  • 4. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD.
    Ann Intern Med; 2020 May 05; 172(9):583-590. PubMed ID: 32150602
    [Abstract] [Full Text] [Related]

  • 5. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Haaland RE, Martin A, Livermont T, Fountain J, Dinh C, Holder A, Lupo LD, Hall L, Conway-Washington C, Kelley CF.
    J Acquir Immune Defic Syndr; 2019 Nov 01; 82(3):252-256. PubMed ID: 31335590
    [Abstract] [Full Text] [Related]

  • 6. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
    Glidden DV, Das M, Dunn DT, Ebrahimi R, Zhao Y, Stirrup OT, Baeten JM, Anderson PL.
    J Int AIDS Soc; 2021 May 01; 24(5):e25744. PubMed ID: 34021709
    [Abstract] [Full Text] [Related]

  • 7. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H.
    BMC Infect Dis; 2024 Jun 06; 24(1):565. PubMed ID: 38844855
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Emtricitabine/tenofovir alafenamide usage in a Scottish sexual health service providing HIV pre-exposure prophylaxis: A service evaluation.
    Burley N, MacDonald R, Khan A.
    Int J STD AIDS; 2024 Mar 06; 35(4):308-310. PubMed ID: 38053307
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo.
    Zivich PN, Cole SR, Edwards JK, Glidden DV, Das M, Shook-Sa BE, Shao Y, Mehrotra ML, Adimora AA, Eron JJ.
    J Infect Dis; 2024 Apr 12; 229(4):1123-1130. PubMed ID: 37969014
    [Abstract] [Full Text] [Related]

  • 12. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R, Spencer H, Bougatsos C, Blazina I, Ahmed A, Selph S.
    JAMA; 2023 Aug 22; 330(8):746-763. PubMed ID: 37606667
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G, Antoni G, Pialoux G, Capitant C, Cotte L, Charreau I, Tremblay C, Cua E, Senneville E, Raffi F, Meyer L, Molina JM, ANRS-IPERGAY study group.
    J Int AIDS Soc; 2020 Feb 22; 23(2):e25420. PubMed ID: 32086878
    [Abstract] [Full Text] [Related]

  • 15. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.
    Basic Clin Pharmacol Toxicol; 2019 Apr 22; 124(4):479-490. PubMed ID: 30388308
    [Abstract] [Full Text] [Related]

  • 16. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I, Kayembe K, Valin N, Rougier H, Shinga BW, Lambert-Niclot S, Chiarabini T, Meyohas MC, Lacombe K.
    BMC Infect Dis; 2023 Sep 04; 23(1):578. PubMed ID: 37667182
    [Abstract] [Full Text] [Related]

  • 17. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
    Patel N, Morris S, Burke L, Chow K, Pacheco D, Anderson P, Stancyzk F, Blumenthal J.
    Br J Clin Pharmacol; 2024 Oct 04; 90(10):2360-2365. PubMed ID: 38646796
    [Abstract] [Full Text] [Related]

  • 18. Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
    Bekerman E, Cox S, Babusis D, Campigotto F, Das M, Barouch DH, Cihlar T, Callebaut C.
    J Antimicrob Chemother; 2021 Feb 11; 76(3):692-698. PubMed ID: 33202006
    [Abstract] [Full Text] [Related]

  • 19. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E.
    Biochem Pharmacol; 2016 Nov 01; 119():1-7. PubMed ID: 27133890
    [Abstract] [Full Text] [Related]

  • 20. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
    Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.
    J Pharmacol Exp Ther; 2018 Nov 01; 367(2):245-251. PubMed ID: 30150483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.